The correlation among the percentage of positive biopsy cores from the dominant side of prostate, adverse pathology, and biochemical failure after radical prostatectomy-Reference-Cited by-同舟云学术

The correlation among the percentage of positive biopsy cores from the dominant side of prostate, adverse pathology, and biochemical failure after radical prostatectomy

Published:2011-08 Issue:8 Volume:27 Page:307-313
ISSN:1607-551X
Container-title:The Kaohsiung Journal of Medical Sciences
language:en
Short-container-title:The Kaohsiung Journal of Medical Sciences

Author:

Memis Ali,Ugurlu Ozgur,Ozden Cuneyt,Oztekin Cetin Volkan,Aktas Binhan Kagan,Akdemir Alp Ozgur

Publisher

Wiley

Subject

General Medicine

Reference20 articles.

1. Cancer statistics;Boring;CA Cancer J Clin,1994

2. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results;Roehl;J Urol,2004

3. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years;Partin;Urol Clin North Am,1993

4. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience;Han;Urol Clin North Am,2001

5. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer;Partin;J Urol,1993

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The percentage of positive biopsy cores in predicting biochemical recurrence and adverse pathology in prostate cancer patients after radical prostatectomy: a systematic review and meta-analysis;Bali Medical Journal;2023-01-20

2. C‐reactive protein and procalcitonin levels in prostate cancer;International Journal of Clinical Practice;2020-12-30

3. Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01–10.0 ng/ml);Journal of Cancer Research and Therapeutics;2017

4. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy;Journal of Urology;2017-01